Table 1. Patients' baseline characteristics.
| Patient characteristics | No. of patients (n=99) | |
|---|---|---|
| Age (yr) | 54 (39–72) | |
| Sex | ||
| Male | 66 (67) | |
| Female | 33 (33) | |
| ECOG PS | ||
| 0 | 40 (40) | |
| 1 | 59 (60) | |
| Stage according to the AJCC 2002 system | ||
| T2 N0 | 51 (52) | |
| T1 N1 | 48 (48) | |
| Type of surgery | ||
| Total gastrectomy | 14 (14) | |
| Subtotal gastrectomy | 85 (86) | |
| WHO histologic classification | ||
| Well | 3 (3) | |
| Moderate | 19 (19) | |
| Poorly or signet ring cell type | 77 (78) | |
| Lauren's classification | ||
| Intestinal | 32 (32) | |
| Diffuse | 63 (64) | |
| Mixed or indeterminate | 4 (4) | |
| Lymphovascular invasion | 41 (41) | |
| Perineural invasion | 35 (35) | |
| No. of regional lymph nodes | ||
| Resected | 37 (15–84) | |
| Positive | 0 (0–6) | |
| Lymph node ratio | 0 (0–0.25) | |
| Adjuvant treatment | ||
| Chemoradiotherapy (XPRT arm) | 49 (49) | |
| Chemotherapy (XP arm) | 50 (51) | |
Values are presented as median (interquartile range) or number (%).
ECOG PS = Eastern Cooperative Oncology Group performance status; AJCC = American Joint Committee on Cancer; WHO = World Health Organization; XPRT = xanthine phosphoribosyltransferase; XP = capecitabine plus cisplatin.